 This is a randomized, open-label, active-control, multicenter trial comparing two oxaliplatinAvastin-based treatment sequences as first-line therapy for metastatic colorectal cancer. The study is designed to compare the efficacy of these two treatment sequences with respect to progression free survival PFS and overall survival. 